HC Wainwright Boosts Maze Therapeutics (NASDAQ:MAZE) Price Target to $110.00

Maze Therapeutics (NASDAQ:MAZE) had its price target lifted by analysts at HC Wainwright from $60.00 to $110.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 246.89% from the company’s current price.

Other equities research analysts have also issued research reports about the company. Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. Guggenheim raised their price target on Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Mizuho raised Maze Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 11th. Wells Fargo & Company started coverage on Maze Therapeutics in a research report on Thursday, December 4th. They issued an “overweight” rating and a $55.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Maze Therapeutics has an average rating of “Buy” and a consensus target price of $64.11.

Maze Therapeutics Stock Down 0.1%

Shares of NASDAQ:MAZE opened at $31.71 on Wednesday. The stock has a market cap of $1.53 billion, a PE ratio of -9.82 and a beta of 4.47. The company’s fifty day moving average is $45.81 and its 200 day moving average is $37.51. Maze Therapeutics has a 52 week low of $6.71 and a 52 week high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Wednesday, March 25th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.08.

Insider Buying and Selling at Maze Therapeutics

In other news, SVP Amy Bachrodt sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $40.58, for a total value of $405,800.00. Following the completion of the sale, the senior vice president directly owned 12,965 shares of the company’s stock, valued at approximately $526,119.70. This trade represents a 43.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CMO Harold Bernstein sold 45,000 shares of Maze Therapeutics stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $1,825,200.00. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 245,000 shares of company stock valued at $10,504,792.

Hedge Funds Weigh In On Maze Therapeutics

Institutional investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Maze Therapeutics in the first quarter worth about $57,000. Goldman Sachs Group Inc. bought a new position in shares of Maze Therapeutics in the 1st quarter worth approximately $145,000. Rhumbline Advisers bought a new position in shares of Maze Therapeutics in the 1st quarter worth approximately $80,000. Geode Capital Management LLC lifted its stake in shares of Maze Therapeutics by 8.8% in the 2nd quarter. Geode Capital Management LLC now owns 231,237 shares of the company’s stock valued at $2,838,000 after purchasing an additional 18,773 shares during the period. Finally, Ensign Peak Advisors Inc purchased a new position in shares of Maze Therapeutics in the 2nd quarter valued at approximately $227,000.

Trending Headlines about Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Maze announced positive topline Phase 2 HORIZON results for MZE829 showing clinically meaningful uACR reductions (35.6% mean reduction in broad AMKD at week 12; stronger reductions in FSGS and non‑diabetic subgroups) and said it will advance MZE829 into a pivotal program — a clear de‑risking milestone for a lead asset. Maze Announces Positive Topline Data
• Positive Sentiment: Analysts reacted with bullish calls and higher targets — HC Wainwright raised its price target to $110 and BTIG reaffirmed a buy with a $46 target — supporting upside expectations if pivotal plans succeed. Analyst Upgrades
• Positive Sentiment: Quarterly results: Maze beat consensus EPS (reported ($0.65) vs. ($0.73) est.) and reiterated a strong cash position (~$360M), which management says funds operations into 2028 — reduces near‑term financing risk. Q4 and FY2025 Report
• Neutral Sentiment: Corporate governance update: Neil Kumar (BridgeBio founder/CEO) joined Maze’s board — signal of industry expertise but longer‑term impact on strategy is uncertain. Board Addition
• Negative Sentiment: Several outlets described the Phase 2 readout as “mixed” and reported a near‑one‑third drop in market cap as investors parsed subgroup vs overall results and durability/clinical design questions — headline framing triggered aggressive profit‑taking. Mixed Midstage Data Coverage
• Negative Sentiment: An executive disclosed a ~$736K insider sale (15,000 shares via option exercise) reported March 20 — such filings can amplify selling pressure during volatile moves even if routine. Insider Sale Report
• Negative Sentiment: Johnson Fistel announced an investigation into potential claims against Maze executives related to investor losses — legal scrutiny can prolong volatility and increase perceived risk. Shareholder Investigation Notice

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.